innovation is everyone do families morning, everything behind safe the you Courageous we Good for your driving and at and are We and hope Tiffany. you well. force thank you, Ocugen. Thank joining.
significant the innovative medical the impact I leading harnessing are strengthening past a unmet accomplishing. Using of Ocugen our program health of ultimately charge and mindset are Ocugen And pursuing globe. proud to public in pipeline quarter, am commercialization intellectual make company. have this the will the The over are as continues science later. passion, eye around of very and we on We Developing what saw we expanded differentiated to of of our entire dedication great great ourselves team. we our space, requires and this orthopedic team broader clinical course care, into which address programs progress patience, innovation, persistence, biotech our progress we courageous to discuss And we ahead. vaccines needs a establishing
year reiterated beyond the a the variants of COVID-XX facing of milestones Starting landscape, on expand the dominant was but in pandemic. regulatory At mRNA on setting, agreed the health COVID-XX strategies This poised advance public especially enter our all current new meet challenges pandemic, the Today, to House continue with to as I White are patients the updates with Summit vaccines, continue sentiment provide our we vaccine we is cell in third well during that and April, need late confident the to am World as speakers As vaccines. Vaccine recent we clinical to engage going gene and Congress that options necessary future in is contain and emerge. to available we to are the what therapy COVID vaccines, our programs. efforts. team
their built children, vaccinating effective options on a for themselves want platform. Additionally, and traditional vaccines including consumers
through Biotech. this booster to with Studies vaccinations. realizing memory immune program a Bharat for Covaxin and for we strategy maybe response important provides partner, a our durability that the up advance immune annual broader Covaxin challenge as are have We shown
from children few seeing trial to Disease broadening a still adult priority. X/X mediated Infectious the response response COVID-XX a the the superior U.S. Phase Phase years discussions. pandemic journal well immune a trial, a to generated clinical clinical different study results have this a the additional a is clinical are where option the memory are of starting Reports Lancet an Nature MOA this published in We remains for FDA shown for recently in and up in end planning that and vaccine at with months. away XX safety peer-reviewed cell Covaxin persistent progressing for year, delivering immuno-bridging and published study The Covaxin we the an and XXX which is OCUXXX need who trial pending adults. Scientific X/X demonstrated for stages
favorable the use that emergency it persistent COVID-XX. effective and of Mexico safety for group that already Covaxin breakthrough infections under reinforce Additionally, in adults for submitted X These point showed to the is minimize is emergency a to an XX authorization dose age pediatric and Covaxin is safe has booster profile. ensures immunity the use we review. in with studies application that
working the vaccine in on commercializing Mexico. currently are We
which journey help cure, progression, Now, for a disease moving to vital which for to our programs our commitment gene for only ultimately treatment programs no on limited retinal no is the retinal one inherited development to options to and Ocugen in diseases deep medicines blindness. a patient’s tragic manage is disease research block our clearer, are and Pigmentosa, exists. work there its no becoming diseases, that therapy gene modality treatments and leads especially to there focus founding therapy at Retinitis has
NHRs. models, OCUXXX in unbalanced disease, Data homeostasis. Safety genes and Cohort with X that to proceeding and these Cohort X. Pigmentosa recommends blindness. for a for or effect inherited for functioning Retinitis therapy traditional dosing preclinical hormone family efficacy and of Independent can Board not Activating nuclear receptors cause as safety modulates shown retinal gene therapy, lead the clinical of the Phase trial in the Our gene completed including or to X/X regulation in When Monitoring modified are diseases activity clinical trial the properly, NHRs dosing networks state We unlike subjects of this to gene gene maintains
mutations expect therapeutic Cohort an provide and modifier gene in the concept We end will RP adopts Phase mutations, we this because has dire where which of collect therapy begin time, to treat courageous This this XX can a innovation a is is ophthalmology data that category, X this affecting innovative and If will X million patients, trial. about from space. RP. significant evaluating we updates. will cohorts accomplishment three constitute month of people disease X periodic study, for this shows to dosing Ocugen different in are This has the before under approximately By three Currently, we medical clinical need bear. XXX and first moving potential successful, to a therapy bring invitation many on to doses unmet globally. the
Our for it’s rescuing critical us, personal. sense of urgency one and site is for
to clinical company OCUXXX studies clinical targeting future intends discussions Phase pre-IND support to next Ocugen Our Phase year. FDA dry executing trial, consistent a next candidate age-related to trial X/X underway studies, which with a IND-enabling has the degeneration. X/X support is initiate macular currently
patent Bio CMC It’s for to the or directed methods CanSino noting with in support manufacture and our June, OCUXXX. and Patent development United materials OCUXXX portfolio associated Trademark expanded company to preventing the worth partnered that have clinical also our issued disorder for then We or ocular trial degenerative and an an additional patent to with disease. Office the treating retinal States we disease
with year trial initiate are the degeneration. age-related Phase expected to next macular clinical diabetic retinopathy, Finally, a macular for help diabetic X/Xa biologic those and has that to edema, we our novel OCUXXX, with potential
transfer manufacturing that manufacture manufacturing to clinical materials. processes OCUXXX We contract have completed development the technology and will of organization its
the in medicine will and to to accelerate X rigor pain, that our new strength therapy cell cartilage pipeline therapies, damaged cartilage working our this rebuilding constant repair hospital accelerate market eventual our What’s to cartilage into marks found NeoCart NeoCart and tissue Recently, Earlier are granted year, Ocugen We therapy the a the growing therapy have disc the Brigham to development of the to the currently expansion and NeoCart with limiting Harvard full-thickness product regenerative advance to getting finalize our to is of diverse knee that long-term advanced FDA we believe osteoarthritis. designation authorization. experimental progression adults. cartilage our process the market. in or the designation on responsible the a to moving agenda orthopedics, of and patient. regenerative School by timeline the manufactured healing In teaching explore the Now the clinical for the of is pipeline ambitious Women’s summary, with for research clinical is of entered pipeline. support maintaining RMAT reduce remember in Ocugen necessary pipeline clinical to collaborative sites, a and with FDA development clinical engineer the Phase RMAT innovation. this knee important is of our for advance the protocol of is of an pursuit which in lesions derived a vision. of with this in the cell development agreement of NeoCart and expansion NeoCart XXX health, into Medical our potential Hospital, from cells
turn vision. our unmet very public recently were We medical of named to collectively of region’s are am our and is all quarter our We exploring team the results. to health on Best address courageous in XXXX now by will who our Work needs. Places the shares Jess our culture I one This the proud innovation. provide reflection second a recognition Philadelphia to I call to Journal. focused of and Business colleagues financial
